...
首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Noradrenaline-induced contraction of human saphenous vein and human internal mammary artery: involvement of different alpha-adrenoceptor subtypes.
【24h】

Noradrenaline-induced contraction of human saphenous vein and human internal mammary artery: involvement of different alpha-adrenoceptor subtypes.

机译:去甲肾上腺素诱导的人大隐静脉和人乳内动脉收缩:参与不同的α-肾上腺素受体亚型。

获取原文
获取原文并翻译 | 示例
           

摘要

Although saphenous veins and internal mammary arteries are commonly used for coronary artery bypass grafting, only a very few comparative studies are available on alpha-adrenoceptor-mediated vasoconstriction in these vessels. Thus, we determined, in isolated rings from human saphenous vein and human internal mammary artery, contractile responses to noradrenaline (10(-8)-10(-4) M) in the absence and presence of the alpha-adrenoceptor antagonists yohimbine (alpha(2)-adrenoceptor antagonist, 10(-8)-10(-6) M), prazosin (alpha(1)-adrenoceptor antagonist, 10(-9)-10(-7) M), 5-methyl-urapidil (5-MU, alpha(1A)-adrenoceptor antagonist, 10(-8)-10(-6) M), BMY 7378 (alpha(1D)-adrenoceptor antagonist, 10(-7)-10(-6) M), and chloroethylclonidine (CEC, irreversible alpha(1B)-adrenoceptor antagonist, 3x10(-5) M for 30 min). All experiments were carried out in the presence of 10(-7) M propranolol and 10(-5) M cocaine. In both vessel types noradrenaline evoked concentration-dependent contractions. In saphenous veins yohimbine was a potent antagonist (pA(2)-value 8.32) while prazosin, 5-MU and BMY exhibited only marginal antagonistic effects. CEC, however, significantly decreased noradrenaline-induced contractions. In contrast, in internal mammary arteries prazosin (pA(2)-value 9.65) and 5-MU (pK(B)-values 7.2-7.5) were potent antagonists, while yohimbine and BMY exhibited only weak antagonistic effects. CEC, however, significantly decreased noradrenaline-induced contractions. We conclude that in saphenous vein the contractile response to noradrenaline is mediated predominantly by alpha(2)-adrenoceptors, while in internal mammary artery it is mediated (to a major part) by alpha(1B)- and (to a minor part) by alpha(1A)-adrenoceptors.
机译:尽管大隐静脉和乳腺内动脉通常用于冠状动脉搭桥术,但是关于这些血管中α-肾上腺素受体介导的血管收缩的比较研究很少。因此,我们确定了在不存在和存在α-肾上腺素受体拮抗剂育亨宾(α)的情况下,在来自人大隐静脉和人乳内动脉的孤立环中,对去甲肾上腺素(10(-8)-10(-4)M)的收缩反应(2)-肾上腺素受体拮抗剂,10(-8)-10(-6)M),哌唑嗪(α(1)-肾上腺素受体拮抗剂,10(-9)-10(-7)M),5-甲基乌拉地尔(5-MU,alpha(1A)-肾上腺素受体拮抗剂,10(-8)-10(-6)M),BMY 7378(alpha(1D)-肾上腺素受体拮抗剂,10(-7)-10(-6)M )和氯乙基可乐定(CEC,不可逆的α(1B)-肾上腺素受体拮抗剂,3x10(-5)M,持续30分钟)。所有实验均在10(-7)M普萘洛尔和10(-5)M可卡因存在下进行。在这两种血管中,去甲肾上腺素都会引起浓度依赖性的收缩。在隐静脉中育亨宾是一种有效的拮抗剂(pA(2)值8.32),而哌唑嗪,5-MU和BMY仅表现出有限的拮抗作用。然而,CEC显着降低了去甲肾上腺素引起的收缩。相反,在乳腺内动脉中,哌唑嗪(pA(2)值为9.65)和5-MU(pK(B)值​​为7.2-7.5)是有效的拮抗剂,而育亨宾和BMY仅表现出弱的拮抗作用。然而,CEC显着降低了去甲肾上腺素引起的收缩。我们得出的结论是,在大隐静脉中,对去甲肾上腺素的收缩反应主要由α(2)-肾上腺素受体介导,而在乳内动脉中,它主要由α(1B)-和(次要)介导。 alpha(1A)-肾上腺素受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号